Try our corporate solution for free!
(212) 419-8286

Top COVID-19 vaccines forecasted sales 2020-2026

It is estimated that the COVID-19 vaccine from the Biontech/Pfizer cooperation will generate over three billion U.S. dollars in sales during 2021. However, there will probably be a steep decrease to 1.4 billion dollars in 2022. The major downside of the Biontech/Pfizer vaccine is its need for ultra-cold storage. Many countries and regions don't have the required cold chain logistics, and probably won't have it in the years to come.

Projected sales of select leading COVID-19 vaccines from 2020 to 2026*

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until March 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

December 2020



Survey time period

as of December 2020

Supplementary notes

* Reliable consensus is not available for Astrazeneca's AZD1222, J&J's Ad26.COV2-S, or Curevac's CVnCoV, all of which are in pivotal development.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Coronavirus: the pharma and medtech response"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.